¼¼°èÀÇ MAXIGESIC IV ½ÃÀå : ½ÃÀå ±Ô¸ð, ¿¹Ãø, »õ·Î¿î ÀλçÀÌÆ®(-2032³â)
MAXIGESIC IV Market Size, Forecast, and Market Insight - 2032
»óǰÄÚµå : 1614784
¸®¼­Ä¡»ç : DelveInsight Business Research LLP
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 30 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,750 £Ü 3,978,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,125 £Ü 5,968,000
PDF (2-3 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 3¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,500 £Ü 7,957,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,250 £Ü 11,936,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

MAXIGESIC IV´Â ½Å±Ô ƯÇã¹ÞÀº µà¾ó ¸ðµå ºñ¿ÀÇÇ¿ÀÀ̵å ÁøÅë Ä¡·áÁ¦·Î ÆÄ¶ó¼¼Å¸¸ô(¹Ì±¹¿¡¼­´Â ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæ) 1,000mg°ú À̺ÎÇÁ·ÎÆæ 300mgÀ» ¹èÇÕÇÑ µ¶ÀÚÀûÀÎ ÁÖÀÔ Á¦Á¦ÀÔ´Ï´Ù.

MAXIGESIC´Â µÎÅë, ÆíµÎÅë, ±äÀ强 µÎÅë, ºÎºñµ¿ ÅëÁõ, Ä¡Åë, Ä¡°ú Ä¡·á, µÚÅë, ÀεÎÅë, °üÀý¿°, Å״Ͻº ¿¤º¸, »ý¸®Åë, ±ÙÀ°Åë, ·ù¸¶Æ¼½º ÅëÁõ, °¨±â ¹× µ¶°¨ ¹ß¿­À» ¾ïÁ¦Çϰí ÀϽÃÀûÀ¸·Î ¿ÏÈ­ÇÕ´Ï´Ù. ºü¸£°í È¿°úÀûÀ¸·Î ¿ÏÈ­ÇÏ´Â °ÍÀ¸·Î ÀÔÁõµÇ¾ú½À´Ï´Ù. ¿¡ º¹¼öÀÇ ¶óÀ̼±½º °è¾à°ú ÆÇ¸Å °è¾àÀ» ü°áÇß½À´Ï´Ù.¹Ì±¹¿¡¼­ÀÇ ½ÂÀÎ ½ÅûÀ» ¼­Æ÷Æ®Çϱâ À§ÇØ, 2¹øÂ°ÀÇ III»ó ½ÃÇèÀÌ Á¾·áÇß½À´Ï´Ù.

º» º¸°í¼­´Â ÁÖ¿ä 7°³±¹ÀÇ MAXIGESIC IV ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç,, ½ÃÀå °³¿ä¿Í ÇÔ²² °æÀï ±¸µµ, 2032³â±îÁö ½ÃÀå ±Ô¸ð ¿¹Ãø, ±¹°¡º° ½ÃÀå ºÐ¼® µîÀ» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå º¸°í¼­ ¼Ò°³

Á¦2Àå ¼ö¼ú ÈÄ ÅëÁõÀÇ MAXIGESIC IV °³¿ä

Á¦3Àå °æÀï ±¸µµ(Ãâ½ÃµÈ Ä¡·á¹ý

Á¦4Àå °æÀï ±¸µµ(Èı⠴ܰèÀÇ ½ÅÈï Ä¡·á¹ý

Á¦5Àå MAXIGESIC IV ½ÃÀå Æò°¡

Á¦6Àå SWOT ºÐ¼®

Á¦7Àå ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

Á¦8Àå ºÎ·Ï

Á¦9Àå DelveInsightÀÇ ¼­ºñ½º ³»¿ë

Á¦10Àå ¸éÃ¥»çÇ×

Á¦11Àå DelveInsight Á¤º¸

Á¦12Àå º¸°í¼­ ±¸¸Å ¿É¼Ç

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

"MAXIGESIC IV Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about MAXIGESIC IV for Postoperative pain in the seven major markets. A detailed picture of the MAXIGESIC IV for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the MAXIGESIC IV for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MAXIGESIC IV market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

MAXIGESIC IV, a novel, patented, dual mode-of-action nonopioid pain treatment, is a unique combination of paracetamol (known as acetaminophen in the US) 1,000 mg + Ibuprofen 300 mg solution for infusion for use postoperatively in hospitals for patients for whom the use of oral analgesics is limited.

MAXIGESIC reduces fever and temporarily relieves pain associated with headaches, migraines, tension headaches, sinus pain, toothache, dental procedures, backache, sore throat, arthritis, tennis elbow, period pain, muscular pain, rheumatic pain, aches and pains associated with colds and flu. The drug is a unique patented combination of paracetamol and ibuprofen, proven to provide fast and effective relief from a wide range of pain symptoms (This information is for New Zealand only) (Maxigesic, n.d.). The product has obtained marketing authorizations in 17 European countries, launched in Australia, New Zealand, and the United Arab Emirates, and multiple license and distribution agreements signed to accelerate roll-out and commercialization in Europe and Hong Kong. The second Phase III study was completed to support regulatory submission in the US.

Dosage and administration

Adults and children over 12 years: The usual dosage is one to two tablets taken every 6 h, as required, up to a maximum of eight tablets in 24 h.

Children under 12 years: It is not recommended for children under 12.

Scope of the Report:

The report provides insights into:

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MAXIGESIC IV Analytical Perspective by DelveInsight

This report provides a detailed market assessment of MAXIGESIC IV for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

The report provides the clinical trials information of MAXIGESIC IV for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

Key Questions:

Table of Contents

1. Report Introduction

2. MAXIGESIC IV Overview in Postoperative pain

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. MAXIGESIC IV Market Assessment

6. SWOT Analysis

7. Analysts' Views

8. Appendix

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â